ONVO.Organovo Holdings, INC

8-K: Organovo Holdings Issues Shares Through At-the-Market Offering, Raising $1.8 Million

Sentiment:

Current Report

📋All filings for Organovo Holdings, INC
🔒Login to Follow

Organovo Holdings has raised approximately $1.8 million through an at-the-market offering by issuing 1,349,778 shares of common stock between February 1, 2024 and April 19, 2024.

Capital raiseThe company has been selling shares through an at-the-market offering.Between February 1, 2024 and April 19, 2024, the company issued 1,349,778 shares for gross proceeds of approximately $1.8 million.The company has an existing agreement to sell up to $50 million in shares through this ATM offering.

Summary

  • Organovo Holdings, Inc. has been selling shares of its common stock through an at-the-market (ATM) offering.
  • The company sold 1,349,778 shares between February 1, 2024, and April 19, 2024.
  • This resulted in gross proceeds of approximately $1.8 million for the company.
  • As of April 19, 2024, Organovo has 11,391,102 shares of common stock issued and outstanding.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is raising capital, which is necessary for operations, but the method of raising capital through an ATM offering can be seen as a sign of financial need.

Positives

  • The company successfully raised $1.8 million through the ATM offering, providing additional capital.

Risks

  • The company's reliance on at-the-market offerings for funding may indicate a need for continuous capital raising.
  • The increase in the number of outstanding shares may dilute the value of existing shares.

Management Comments

  • Keith Murphy, Executive Chairman, signed the report on behalf of the company.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital without the need for a large, dilutive secondary offering.

Comparison to Industry Standards

  • Many small-cap biotech companies use ATM offerings to raise capital, especially when their stock price is volatile or when they need to fund ongoing research and development.
  • The amount raised, $1.8 million, is relatively small compared to larger capital raises in the biotech industry, but is typical for companies of Organovo's size and stage.

Stakeholder Impact

  • Shareholders may experience dilution due to the increase in the number of outstanding shares.
  • The company's ability to fund operations is improved by the capital raise.

Key Dates

DateDescription
March 16, 2018Organovo entered into a Sales Agreement with H.C. Wainwright & Co., LLC and JonesTrading Institutional Services LLC for an at-the-market offering.
February 1, 2024Start date of the period during which 1,349,778 shares were issued.
April 19, 2024End date of the period during which 1,349,778 shares were issued and the date the company had 11,391,102 shares outstanding.
April 23, 2024Date the 8-K report was signed.

Keywords

at-the-market offering, common stock, capital raise, share issuance, Organovo Holdings

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.